Total Payments
$2.2M
2024 Payments
$218,979
Companies
53
Transactions
2,045
Payment Breakdown by Category
Consulting$1.4M (63.0%)
Other$364,921 (16.6%)
Travel$235,626 (10.7%)
Research$181,923 (8.3%)
Food & Beverage$28,333 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1.4M | 407 | 63.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $277,551 | 101 | 12.7% |
| Travel and Lodging | $235,626 | 415 | 10.7% |
| Unspecified | $181,923 | 186 | 8.3% |
| Honoraria | $82,871 | 29 | 3.8% |
| Food and Beverage | $28,333 | 906 | 1.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,500 | 1 | 0.2% |
Payments by Type
General
$2.0M
1,859 transactions
Research
$181,923
186 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $388,056 | 308 | $0 (2024) |
| GENZYME CORPORATION | $364,016 | 183 | $0 (2024) |
| LEO Pharma AS | $204,610 | 198 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $176,058 | 92 | $0 (2023) |
| ABBVIE INC. | $174,711 | 280 | $0 (2024) |
| Eli Lilly and Company | $154,564 | 75 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $108,216 | 131 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $84,558 | 147 | $0 (2024) |
| Amgen Inc. | $83,890 | 70 | $0 (2024) |
| Incyte Corporation | $53,416 | 114 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $218,979 | 282 | GENZYME CORPORATION ($51,028) |
| 2023 | $223,897 | 268 | GENZYME CORPORATION ($64,823) |
| 2022 | $265,619 | 290 | ABBVIE INC. ($48,623) |
| 2021 | $273,467 | 150 | PFIZER INC. ($61,120) |
| 2020 | $330,870 | 151 | PFIZER INC. ($85,926) |
| 2019 | $330,763 | 362 | PFIZER INC. ($78,747) |
| 2018 | $356,037 | 326 | GENZYME CORPORATION ($126,684) |
| 2017 | $193,133 | 216 | Regeneron Healthcare Solutions, Inc. ($32,249) |
All Payment Transactions
2,045 individual payment records from CMS Open Payments — Page 1 of 82
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $265.52 | General |
| Category: IMMUNOLOGY | ||||||
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $7.86 | General |
| Category: IMMUNOLOGY | ||||||
| 12/23/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: IMMUNOLOGY | ||||||
| 12/23/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $6.35 | General |
| Category: IMMUNOLOGY | ||||||
| 12/20/2024 | LEO Pharma AS | — | Consulting Fee | Cash or cash equivalent | $6,335.00 | General |
| 12/19/2024 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| 12/19/2024 | PFIZER INC. | LITFULO (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: LITFULO CLINICAL PUBLICATION PROGRAM • Category: IMMUNOLOGY | ||||||
| 12/19/2024 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| 12/19/2024 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $64.59 | General |
| 12/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.01 | General |
| Category: Immunology | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $10.07 | General |
| Category: Immunology | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $7.87 | General |
| Category: Immunology | ||||||
| 12/14/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $83.58 | General |
| Category: DERMATOLOGY | ||||||
| 12/13/2024 | PFIZER INC. | LITFULO (Drug) | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $24.93 | General |
| Category: Dermatology | ||||||
| 12/09/2024 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.63 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $47.16 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $12,600.00 | General |
| 11/26/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 11/26/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $3,800.00 | Research |
| Study: A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | ||||||
| 11/22/2024 | Amgen Inc. | — | Travel and Lodging | Cash or cash equivalent | $367.86 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $37,540 | 37 |
| RITLECITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $36,070 | 25 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $31,538 | 38 |
| CRISABOROLE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $10,950 | 12 |
| AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $7,915 | 15 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN PATIENTS >=12 TO <18 YEARS OF AGE, WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $7,312 | 8 |
| A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $5,340 | 7 |
| M16-048 | AbbVie, Inc. | $4,981 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY INVESTIGATING THE EFFICACY, SAFETY, SERUM CONCENTRATION AND BIOMARKER PROFILE OF DUPILUMAB ADMINISTERED TO ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $4,711 | 5 |
| CC-10004-AD-001 - A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Celgene Corporation | $4,022 | 1 |
| LITFULO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,860 | 3 |
| A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | Takeda Pharmaceuticals U.S.A., Inc. | $3,800 | 1 |
| HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR) | Regeneron Pharmaceuticals, Inc. | $3,164 | 3 |
| A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients 12 to 18 Years of Age, With Moderate-to-severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $2,357 | 6 |
| SAFETY AND TOLERABILITY OF LEO 138559 IN HEALTHY SUBJECTS AND SUBJECTS WITH ATOPIC DERMATITIS | LEO Pharma AS | $1,950 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy, Safety, Serum Concentration and Biomarker Profile of Dupilumab Administered to Adult Patients With Mode | SANOFI-AVENTIS U.S. LLC | $1,791 | 2 |
| Prospective, Observational, Longitudinal Study in Pediatric Patients With Moderate to Severe Atopic Dermatitis Whose Disease is Not Adequately Controlled With Topical Prescription Therapies or When Those Therapies Are Not Medically Advisable | Regeneron Pharmaceuticals, Inc. | $1,544 | 2 |
| A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody KHK4083 in Subjects with Moderate to Severe Atopic Dermatitis AD | Kyowa Kirin Pharmaceutical Development, Inc | $1,300 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | GENZYME CORPORATION | $1,250 | 1 |
| JAK 3TEC CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $780.00 | 1 |
| A Phase 2a Study Investigating the Safety, Pharmacokinetics, Immunogenicity, and Exploratory Efficacy of Dupilumab in Patients Aged 6 to 18 Years With Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $504.06 | 1 |
| A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | GENZYME CORPORATION | $500.00 | 1 |
| An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $324.00 | 1 |
| Dupixent Clinical Development Program | Regeneron Pharmaceuticals, Inc. | $292.91 | 2 |
| Real-world Effectiveness of Dupilumab in Atopic Dermatitis: Improvement in Itch as Assessed by the Peak Pruritus Numerical Rating Scale in an Electronic Medical Records Dataset | SANOFI-AVENTIS U.S. LLC | $289.09 | 1 |
| SOLO 1; SOLO 2 | SANOFI-AVENTIS U.S. LLC | $287.32 | 1 |
| Patient-reported Disease Burden in Adults with Atopic Dermatitis in the Clinical Practice Setting and Impact of Inadequately Controlled Disease: A US Cross-sectional Study | SANOFI-AVENTIS U.S. LLC | $184.88 | 2 |
| Modernizing Medicine: IGA & NRS | SANOFI-AVENTIS U.S. LLC | $152.19 | 1 |
| Persistence to Dupilumab in Adults with Atopic Dermatitis | SANOFI-AVENTIS U.S. LLC | $152.19 | 1 |
About Dr. Emma Guttman, MD
Dr. Emma Guttman, MD is a Dermatology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/08/2008. The National Provider Identifier (NPI) number assigned to this provider is 1053556852.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Emma Guttman, MD has received a total of $2.2M in payments from pharmaceutical and medical device companies, with $218,979 received in 2024. These payments were reported across 2,045 transactions from 53 companies. The most common payment nature is "Consulting Fee" ($1.4M).
Ad
Practice Information
- Specialty Dermatology
- Location New York, NY
- Active Since 12/08/2008
- Last Updated 06/09/2011
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1053556852
Products in Payments
- DUPIXENT (Biological) $273,760
- DUPIXENT (Drug) $240,021
- EUCRISA (Drug) $120,063
- DUPIXENT DUPILUMAB INJECTION (Biological) $103,951
- CIBINQO (Drug) $36,184
- RINVOQ (Biological) $35,558
- TREMFYA (Drug) $28,343
- Enbrel (Biological) $14,075
- Humira (Biological) $12,601
- NO PRODUCT DISCUSSED (Drug) $11,955
- OPZELURA (Drug) $11,066
- LITFULO (Drug) $9,426
- TALTZ (Drug) $9,353
- ADBRY (Biological) $8,732
- Otezla (Drug) $8,660
- QBREXZA (Drug) $7,586
- TEZSPIRE (Biological) $6,850
- Parsabiv (Biological) $5,850
- Tremfya (Drug) $5,354
- XALKORI (Drug) $5,200
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in New York
David Cohen, M.d, M.D
Dermatology — Payments: $3.1M
Dermatology $3.1M
Dr. Amy Wechsler, M.d, M.D
Dermatology — Payments: $2.8M
Dermatology $2.8M
Dr. Alexandra Golant, M.d, M.D
Dermatology — Payments: $2.7M
Dermatology $2.7M
Dr. Joshua Zeichner, Md, MD
Dermatology — Payments: $2.1M
Dermatology $2.1M
Dr. Mark Lebwohl
Dermatology — Payments: $2.0M
Dermatology $2.0M
Mr. Michael Cameron
Dermatology — Payments: $1.9M
Dermatology $1.9M